Cell No. 4 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Cell No. 4 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Press Releases

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

January 9, 2017

BioCentury - Viral Vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that make cancerous cells vulnerable to antiviral treatment. Read More

November 30, 2016

Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics

San Diego and London; November 30, 2016 – Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. Viracta plans to advance VRx-3996 (previously CHR-3996) into Phase 2 clinical testing for application in Viracta’s proprietary anticancer combination therapy approach. The Company will initially focus on Epstein Barr Virus-associated lymphoid malignancies. Read More

Events

February 28 - March 1, 2018

Biocom's Global Life Science Partnering Conference

David Slack will be presenting at Biocom's Global Life Science Partnering Conference in San Diego Read More

April 20, 2017

The 8th China-US Business Leaders Conference

Ivor Royston will speak at The 8th China-US Business Leaders Conference in New York City Agenda | Ascentage Forum

April 7, 2017

24th Annual Future Leaders in the Biotech Industry Conference, New York City

Viracta selected to present at BioCentury’s Future Leaders in the Biotech Industry Conference Read More

January 9, 2017

9th Annual Biotech Showcase Conference

Viracta will present at the 9th Annual Biotech Showcase Conference in San Francisco Read More

January 9-13, 2017

J.P. Morgan Healthcare Conference

J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco Read More

Press Releases

April 11, 2018

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

San Diego, CA, April 11, 2018 - Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient in a Phase 1b/2 clinical trial in Epstein-Barr virus-positive (EBV+) lymphomas. The Company’s unique therapeutic approach is the first targeted, orally administered therapy for EBV+ lymphomas. Read More

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership

Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

January 9, 2017

BioCentury - Viral Vulnerability

Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that make cancerous cells vulnerable to antiviral treatment. Read More

November 30, 2016

Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics

San Diego and London; November 30, 2016 – Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. Viracta plans to advance VRx-3996 (previously CHR-3996) into Phase 2 clinical testing for application in Viracta’s proprietary anticancer combination therapy approach. The Company will initially focus on Epstein Barr Virus-associated lymphoid malignancies. Read More

Events

February 28 - March 1, 2018

Biocom's Global Life Science Partnering Conference

David Slack will be presenting at Biocom's Global Life Science Partnering Conference in San Diego Read More

April 20, 2017

The 8th China-US Business Leaders Conference

Ivor Royston will speak at The 8th China-US Business Leaders Conference in New York City Agenda | Ascentage Forum

April 7, 2017

24th Annual Future Leaders in the Biotech Industry Conference, New York City

Viracta selected to present at BioCentury’s Future Leaders in the Biotech Industry Conference Read More

January 9, 2017

9th Annual Biotech Showcase Conference

Viracta will present at the 9th Annual Biotech Showcase Conference in San Francisco Read More

January 9-13, 2017

J.P. Morgan Healthcare Conference

J.P. Morgan 35th Annual Healthcare Conference 2017 in San Francisco Read More

Publications

A Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies, Perrine...Faller et al, Blood.

Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents, Ghosh...Faller et al, Blood.

A phase 1 pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class 1 selective histone deacetylase inhibitor in refractory solid tumors, Banerji et al, Cancer Clinical Research.

Discovery of 2-(6-{[6-fluoroquinolin-2-yl)methyl]amino}bicycle[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5carboxamide (CHR-3996), a class 1 selective orally active histone deacetylase inhibitor, Moffat et al, Journal of Medicinal Chemistry.